Cipla Reports Highest-Ever Annual Revenue of Rs 28,163 Crore in FY26
New Delhi: Cipla on Tuesday reported its highest-ever annual revenue of Rs 28,163 crore for the financial year 2025-26, driven by strong growth across its India business, Africa operations and differentiated portfolio in the US market.
The company posted consolidated revenue from operations of Rs 28,163 crore in FY26, compared to Rs 27,548 crore in FY25, reflecting a 2 per cent year-on-year growth. Profit after tax (PAT) for the year stood at Rs 3,879 crore, while EBITDA was reported at Rs 5,925 crore with a margin of 21 per cent.
For the quarter ended March 31, 2026, Cipla reported revenue from operations of Rs 6,541 crore. Quarterly PAT stood at Rs 555 crore, while EBITDA came in at Rs 997 crore with a margin of 15.2 per cent.
The company’s One India business recorded a robust 15 per cent year-on-year growth during the quarter, supported by double-digit growth across branded prescription, trade generics and consumer health businesses. Cipla said key chronic therapies including respiratory, urology, anti-diabetes and cardiac segments continued to perform strongly.
In North America, the company posted quarterly revenue of USD 155 million, supported by demand for differentiated products and steady base business. Cipla also received regulatory approval for the first AB-rated gVentolin with CGT, marking the first commercial metered-dose inhaler product manufactured from its US facility.
According to the company’s press release, the One Africa business delivered 14 per cent year-on-year growth in USD terms during the quarter, while the Emerging Markets and Europe business recorded revenue of USD 90 million despite geopolitical uncertainties.
Commenting on the performance, Achin Gupta, MD and Global CEO of Cipla Ltd, said the company continued to make considerable progress across its focused markets and maintained growth momentum across core businesses despite near-term market challenges.
Cipla further stated that the USFDA completed inspections at its manufacturing facilities in Bommasandra, Sitec and Medispray, with all facilities receiving either “VAI” or “NAI” classification.
The Board of Directors has also recommended a final dividend of Rs 13 per equity share for FY26, subject to shareholder approval at the upcoming annual general meeting.
